share_log

Chardan Capital Reiterates Buy on Arbutus Biopharma, Maintains $4 Price Target

Benzinga ·  May 3 09:21

Chardan Capital analyst Keay Nakae reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $4 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment